Jan. 10, 2013
-- Controlled release remains one of the most important innovate areas in pharma, with revenues set to dramatically increase to 2020. Recent advances in drug delivery systems have created the perfect mix for opportunities in the field.
SMi's 10th annual Controlled Release conference http://www.smi-
to be held in London on 18 & 19 March, will continue its long tradition of bringing together critically-acclaimed speakers to debate how controlled release products and drugs have developed over the past 12 months. Key issues up for discussion this year will include investigating structure-activity relationships of siRNA nanoparticles and the challenges of pre-clinical gastro-retentive dosage form development. In addition, large pharma laboratories will present case studies such as GSKs formulation development programme.
Among the speaker faculty this year:
- Andy Lewis, Director Novel Formulation Technologies, Ipsen (Andy is also Board Director at the Controlled Release Society)
- David Elder, Externalisation Director, GlaxoSmithKline
- Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma
- Petra Wicklandt, CMC-Development, Merck & Co
SMi has a rich history of taking a great deal of time to prepare conferences sourcing key opinion leaders in their field. Content is designed deliberately to be topical, timely and relevant. Each conference is tailored to provide delegates with the opportunity to learn, engage and network with their industry peers and professionals. Each event has an average of 16 -18 speakers and all content is available to delegates online during and after the event.
For more information visit http://www.smi-online.co.uk/goto/controlledrelease48.asp
or contact Fateja Begum
on +44 0 20 7827 6184 or email firstname.lastname@example.org